Weight-loss jabs could help tackle depression

Sydney Morning Herald

17-05-2025

The class of medication includes semaglutide, marketed as Ozempic for treatment of diabetes, and Wegovy for weight loss, as well as Mounjaro, which treats both.
Experts have likened the medications to 'the fountain of youth' because of the impact they have had in turning back the clock on a host of diseases.
Scientists believe the ability of the jabs to reduce inflammation and insulin resistance are key to this, with both linked to a number of illnesses as well as depression and cognitive decline.
Previous research has shown diabetes can affect thinking ability, causing memory loss and brain fog.
GLP-1 injections may help fix that by reducing inflammation in the brain, improving how insulin works in the body while boosting the brain's metabolism.
Experts believe these mechanisms may even help the jabs to protect against diseases such as Alzheimer's.
The latest review looked at studies that included obese patients, some of whom had type 2 diabetes.
Patients were being treated with various types of injections, the best-known of which is semaglutide – Ozempic or Wegovy.
In patients without mental illness, the drugs consistently outperformed insulin and other diabetes medications in boosting emotional wellbeing.
The review also appeared to disprove early concerns that the drugs increased the risk of suicidal behaviour, new mental illness or psychiatric hospital admissions.
Five trials reported improved mood and quality of life in patients with conditions such as schizophrenia and bipolar disorder.
Dr Breit said: 'These results are particularly important for people with severe mental disorders who are three times more likely to be living with obesity than the general population.
'This research provides much-needed evidence in support of GLP-1 RAs to help safely address the burden of obesity in people with mental illness.
'However, more data from large-scale randomised trials, and longer treatment and follow-up periods, are needed to establish the long-term efficacy of GLP-1 RAs, as well as future studies exploring whether these medications might be useful for the direct treatment of mental health disorders.'
Mental illnesses are associated with an increased risk of weight gain and type 2 diabetes.
Weight gain is also a common side effect of mood-altering drugs, including antidepressants and antipsychotics, especially for individuals with severe mental illnesses who must take their medications indefinitely to reduce the risk of symptom relapse.
Professor Kamila Hawthorne, chairman of Britain's Royal College of GPs, said: 'This research makes for interesting reading and, as more research is conducted and published, it's important that findings are considered, as clinical guidelines for use of liraglutide, semaglutide and other weight-loss medications are updated and developed.
'There is clearly a lot of potential for weight-loss drugs – which are still very new medications – to have wide-ranging benefits for patients, so it's good to see research being undertaken to explore these.
'As with any medication, they do not come without risk and can cause side effects, which range in seriousness.
Loading
'It's vital that patients have access to the holistic support and care that addresses the underlying reasons for their health problems, rather than relying on medical interventions alone.'
One randomised controlled trial involving 732 patients with type 2 diabetes but no pre-existing mental disorders showed those put on the jabs saw boosts in emotional health and positive feelings, and a reduction in psychological distress.
The weight-loss drugs also appeared to improve symptoms in patients suffering with mental illnesses.